Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

Cited by (785)

Items 201–300 of 785

1. The Diagnosis and Management of Cerebrovascular Disease in Diabetes
   Michael Phipps, Ania M. Jastreboff, Karen L. Furie, Walter N. Kernan · 2012 · Current Diabetes Reports
2. Effects of Blood Pressure Lowering in Patients with Acute Ischemic Stroke and Carotid Artery Stenosis
   Mirza Jusufovic, Else Charlotte Sandset, Philip M. Bath, Björn Wilgot Karlson, Eivind Berge · 2014 · International Journal of Stroke
3. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline
   Alberto Zanchetti, Lisheng Liu, Giuseppe Mancia, Gianfranco Parati, Guido M. Grassi, Marco Stramba‐Badiale, Vincenzo Silani, Grzegorz Bilo, Giovanni Corrao, Antonella Zambon et al. · 2014 · Journal of Hypertension
4. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study
   Henry A. Punzi, Joel M. Neutel, Dean J. Kereiakes, Ali Shojaee, William F. Waverczak, Robert Dubiel, Jen‐Fue Maa · 2010 · Therapeutic Advances in Cardiovascular Disease
5. 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension
   Jinho Shin, Jeong Bae Park, Kwang‐Il Kim, Ju Han Kim, Dong Heon Yang, Wook Bum Pyun, Young Gweon Kim, Gheun‐Ho Kim, Shung Chull Chae · 2015 · Clinical Hypertension
6. Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
   Liping Liu, Xuewei Xie, Yuesong Pan, Aili Wang, Yufei Wei, Jingyi Liu, Ximing Nie, Dacheng Liu, Zilin Zhao, Penglian Wang et al. · 2023 · BMJ
7. Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
   Hean Teik Ong, Loke Meng Ong, Jacqueline J Ho · 2013 · ISRN Cardiology
8. Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida
   Blanca Fuentes, J. Gállego, Antonio Gil-Núñez, Ana Morales, Francisco F. Purroy, Jaume Roquer, Tomás Segura, Javier Tejada, Aida Pilar Lago, Exuperio Díez‐Tejedor et al. · 2011 · Neurología
9. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
   W.J. Elliott · 2009 · Yearbook of Cardiology
10. Capítulo 3 - Avaliação Clínica e Complementar
    Marcus Vinícius Bolívar Malachias, WKSB Souza, Frida Liane Plavnik, CIS Rodrigues, AA Brandão, Mário Fritsch Neves, Luiz Aparecido Bortolotto, RJS Franco, CEP Figueiredo, PCBV Jardim et al. · 2016 · Arquivos Brasileiros de Cardiologia
11. Associations of Cerebrovascular Regulation and Arterial Stiffness With Cerebral Small Vessel Disease: A Systematic Review and Meta‐Analysis
    Britton Scheuermann, Shannon K. Parr, Kiana Marie Schulze, Olivia Nicole Kunkel, Vanessa‐Rose G. Turpin, Jia Liang, Carl J. Ade · 2023 · Journal of the American Heart Association
12. 2010 Canadian Hypertension Education Program (CHEP) recommendations: The scientific summary – an update of the 2010 theme and the science behind new CHEP recommendations
    Norm R.C. Campbell, Janusz A. Kaczorowski, Richard Z Lewanczuk, Ross D. Feldman, Luc Poirier, Margaret Moy Lum-Kwong, Marcel Lebel, Finlay Aleck McAlister, Sheldon W. Tobe · 2010 · Canadian Journal of Cardiology
13. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study
    Jung Hoon Yang, Joo‐Yong Hahn, Yuping Song, Seung‐Hyuk Choi, Jin‐Ho Choi, Sang Hyun Lee, Myung Ho Jeong, Dong‐Ju Choi, J. S. Park, H. S. Park et al. · 2014 · BMJ
14. Blood Pressure: The Lower, the Better
    Ehud Grossman · 2011 · Diabetes Care
15. Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Qianqian Yang, Ruizhi Zheng, Siyu Wang, Jiamin Zhu, Mian Li, Tiange Wang, Zhiyun Zhao, Min Xu, Jieli Lu, Yuhong Chen et al. · 2023 · Hypertension
16. Small Vessel Cerebrovascular Disease: The Past, Present, and Future
    Réza Behrouz, Ali R. Malek, Michel Torbey · 2012 · Stroke Research and Treatment
17. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials
    Massimo Volpe, Giuliano Tocci, Sebastiano Sciarretta, Paolo Verdecchia, Bruno Trimarco, Giuseppe Mancia · 2009 · Journal of Hypertension
18. Inclusion of Stroke as an Outcome and Risk Equivalent in Risk Scores for Primary and Secondary Prevention of Vascular Disease
    Mandip S. Dhamoon, Mitchell S.V. Elkind · 2010 · Circulation
19. Angiotensin II Receptor Blockers and Cancer Risk
    Yun-Tao Zhao, Pengyang Li, Jian-Qiang Zhang, Lei Wang, Yi Zhong · 2016 · Medicine
20. Angiotensin II promotes pulmonary metastasis of melanoma through the activation of adhesion molecules in vascular endothelial cells
    Shin Ishikane, Hiroshi Hosoda, Takashi Nojiri, Takeshi Tokudome, Tetsuya Mizutani, Koichi Miura, Yoshiharu Akitake, Tōru Kimura, Yoshitaka Imamichi, Shinya Kawabe et al. · 2018 · Biochemical Pharmacology
21. Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer
    Thomas Datzmann, Susanne Fuchs, Daniel Andrée, Bernd Hohenstein, Jochen M. Schmitt, Christoph Schindler · 2019 · European Journal of Internal Medicine
22. Role of Time-of-Day of Hypertension Treatment on the J-Shaped Relationship Between Blood Pressure and Cardiovascular Risk
    Ramón C. Hermida, Diana E. Ayala, Artemio Mojón, José Ramón Fernández · 2012 · Chronobiology International
23. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis
    Gabriel L.O. Salvador, Vinicius M Marmentini, Willian R Cosmo, L Emilton · 2017 · European Journal of Preventive Cardiology
24. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
    Chi‐Hung Liu, Tsong-Hai Lee, Yu‐Sheng Lin, Pi‐Shan Sung, Yi‐Chia Wei, Yanrong Li · 2020 · Cardiovascular Diabetology
25. Renin-Angiotensin-Aldosterone System Inhibition
    Kelly Mercier, Holly D. Smith, Jason I. Biederman · 2014 · Primary Care Clinics in Office Practice
26. Renin–Angiotensin System Modulators Modestly Reduce Vascular Risk in Persons With Prior Stroke
    Meng Lee, Jeffrey L. Saver, Keun‐Sik Hong, Qing Hao, Jessica L. Chow, Bruce I Ovbiagele · 2011 · Stroke
27. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?
    Maciej Banach, Marta Michalska, Sverre Erik Kjeldsen, Jolanta Małyszko, Dimitri P. Mikhailidis, Jacek Rysz · 2011 · Expert Opinion on Pharmacotherapy
28. Causes and Secondary Prevention of Acute Ischemic Stroke in Adults
    Märit Jensen, Götz Thomalla · 2019 · Hämostaseologie
29. Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
    Giorgio Battista Boncoraglio, Cinzia Del Giovane, Irene Tramacere · 2021 · Stroke
30. Secondary Prevention of Stroke in the Elderly: A Review of the Evidence
    Ahmed Alhusban, Susan C. Fagan · 2011 · The American Journal of Geriatric Pharmacotherapy
31. Low Glomerular Filtration Rate, Recurrent Stroke Risk, and Effect of Renin–Angiotensin System Modulation
    Bruce Ovbiagele, Philip M. Bath, Daniel Cotton, Nanshi Sha, Hans‐Christoph Diener · 2013 · Stroke
32. Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention
    Chia‐Yu Hsu, Jeffrey L. Saver, Bruce I Ovbiagele, Yi‐Ling Wu, Chun-Yu Cheng, Meng Lee · 2023 · JAMA Neurology
33. Efficacy and Safety of Angiotensin Receptor Blockers in Older Patients: A Meta-Analysis of Randomized Trials
    Islam Y. Elgendy, Tianyao Huo, Veronica Chik, Carl J. Pepine, Anthony A. Bavry · 2014 · American Journal of Hypertension
34. Copper-catalyzed Direct 2-Arylation of Benzoxazoles and Benzoimidazoles with Aryl Bromides and Cytotoxicity of Products
    Nan-Nan Jia, Xin‐Chuan Tian, Xiaoxia Qu, Xingxiu Chen, Yanan Cao, Yunxin Yao, Feng Gao, Xian‐Li Zhou · 2017 · Scientific Reports
35. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus
    Xiaodan lv, Yingshi Zhang, Yixuan Niu, Qi Song, Qingchun Zhao · 2018 · Medicine
36. Long-Term Secondary Prevention: Management of Blood Pressure After a Transient Ischemic Attack or Stroke
    Iain John McGurgan, Peter J. Kelly, Tanya N. Turan, Peter Malcolm Rothwell · 2022 · Stroke
37. Pharmacotherapy for the Secondary Prevention of Stroke
    Ḱazunori Toyoda · 2009 · Drugs
38. Guidelines for the preventive treatment of ischaemic stroke and TIA (I). Update on risk factors and life style
    Blanca Fuentes, J. Gállego, Antonio Gil-Núñez, Ana Morales, Francisco F. Purroy, Jaume Roquer, Tomás Segura, Javier Tejada, Aida Pilar Lago, Exuperio Díez‐Tejedor et al. · 2012 · Neurología (English Edition)
39. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
    Csaba Farsang · 2011 · Vascular Health and Risk Management
40. Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients
    Deng-feng Geng, Dongmei Jin, Wei Wu, Yun Xu, Jingfeng Wang · 2010 · International Journal of Cardiology
41. Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE
    John Philip Chalmers, Hisatomi Arima · 2010 · Journal of Cardiovascular Pharmacology
42. Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke
    Kiyoshi Kikuchi, Hisaaki Uchikado, Motohiro Morioka, Yoshinaka Murai, Eiichiro Tanaka · 2012 · International Journal of Molecular Sciences
43. Secondary prevention of stroke
    Niall MacDougall, Sanjay Amarasinghe, Keith W. Muir · 2009 · Expert Review of Cardiovascular Therapy
44. Angiotensin receptor blockers: baseline therapy in hypertension?
    Franz H. Messerli, Sripal Bangalore, Frank Thomas Ruschitzka · 2009 · European Heart Journal
45. Capítulo 14 – Crise Hipertensiva
    Marcus Vinícius Bolívar Malachias, WKSB Souza, Frida Liane Plavnik, CIS Rodrigues, AA Brandão, Mário Fritsch Neves, Luiz Aparecido Bortolotto, RJS Franco, CEP Figueiredo, PCBV Jardim et al. · 2016 · Arquivos Brasileiros de Cardiologia
46. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT
    Alberto Zanchetti, Lisheng Liu, Giuseppe Mancia, Gianfranco Parati, Guido M. Grassi, Marco Stramba‐Badiale, Vincenzo Silani, Grzegorz Bilo, Giovanni Corrao, Antonella Zambon et al. · 2016 · Journal of Hypertension
47. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure — A network meta-analysis
    Fabrizio Ricci, Augusto Filippo Di Castelnuovo, Gianluigi Savarese, Pasquale Perrone Filardi, Raffaele De Caterina · 2016 · International Journal of Cardiology
48. The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence
    Lucas Miranda Kangussu, Lucas Alexandre Santos Marzano, Cássio Ferraz Souza, Carolina Couy Dantas, Aline Silva de Miranda, Ana Cristina Simões e Silva · 2019 · Protein and Peptide Letters
49. Angiotensin Receptor Blocker and Dihydropyridine Calcium Channel Blocker Combinations: An Emerging Strategy in Hypertension Therapy
    Suzanne Oparil, Michael A. Weber · 2009 · Postgraduate Medicine
50. The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man
    Roberto Pedrinelli · 2009 · Vascular Health and Risk Management
51. Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?
    Michel Azizi, Joël Ménard · 2012 · Cardiovascular Drugs and Therapy
52. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine
    Roberto Ferrari · 2008 · Current Medical Research and Opinion
53. Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials
    İlke Sipahi · 2022 · PLoS ONE
54. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs
    Hans‐Christoph Diener · 2009 · Journal of Hypertension
55. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
    Massimo Volpe, Giuliano Tocci · 2012 · Vascular Health and Risk Management
56. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease
    Wuxiang Xie, Fanfan Zheng, Εvangelos Εvangelou, Ou Liu, Zhenchun Yang, Queenie M Chan, Paul Elliott, Yangfeng Wu · 2018 · Journal of Hypertension
57. Evidence Relating Sodium Intake to Blood Pressure and CVD
    Martin James O'Donnell, Andrew Mente, Salim Yusuf · 2014 · Current Cardiology Reports
58. Comparing angiotensin II receptor blockers on benefits beyond blood pressure
    Helmy M. Siragy · 2010 · Advances in Therapy
59. What Should Be the Target Blood Pressure in Elderly Patients With Diabetes?
    Anna Solini, Ehud Grossman · 2016 · Diabetes Care
60. Management of Hypertension Using Olmesartan Alone or in Combination
    Xiaoshen Zhang, Han Zhang, Yuxia Ma, Wenliang Che, Michael Richard Hamblin · 2017 · Cardiology and Therapy
61. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure
    Costas Thomopoulos, Gianfranco Parati, Alberto Zanchetti · 2017 · Journal of Hypertension
62. Optimization of self-microemulsifying drug delivery system for phospholipid complex of telmisartan using D-optimal mixture design
    Ho Yong Son, Bo Ram Chae, Ji Yeh Choi, Dong Jun Shin, Yoon Tae Goo, Eun Seok Lee, Tae Hoon Kang, Chang Hyun Kim, Ho Yub Yoon, Young Wook Choi · 2018 · PLoS ONE
63. Angiotensin II Type 1 Receptor Blocker Telmisartan Reduces Cerebral Infarct Volume and Peri-infarct Cytosolic Phospholipase A 2 Level in Experimental Stroke
    Tomonori Kobayashi, Takakazu Kawamata, Noriyuki Shibata, Yoshikazu Okada, Makio Kobayashi, Tomokatsu Hori · 2009 · Journal of Neurotrauma
64. Utility of Framingham Coronary Heart Disease Risk Score for Predicting Cardiac Risk After Stroke
    Amytis Towfighi, Daniela Markovic, Bruce Ovbiagele · 2012 · Stroke
65. Treatment of Risk Factors to Prevent Stroke
    Junya Aoki, Ken Uchino · 2011 · Neurotherapeutics
66. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
    Bodh I. Jugdutt · 2010 · Clinical Interventions in Aging
67. Staggered Rather Than Staged or Simultaneous Surgical Strategy May Reduce the Risk of Acute Kidney Injury in Patients Undergoing Bilateral TKA
    Won Uk Koh, Ha‐Jung Kim, Hee‐Sun Park, Minjeong Jang, Young‐Jin Ro, Jun‐Gol Song · 2018 · Journal of Bone and Joint Surgery
68. Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?
    Hean Teik Ong · 2009 · The Journal of the American Board of Family Medicine
69. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
    Sophia Zoungas, Anushka A Patel · 2010 · Annals of the New York Academy of Sciences
70. Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care
    Carl J. Pepine · 2010 · Annals of Medicine
71. Stroke Prevention — Insights from Incoherence
    David M. Kent, David E. Thaler · 2008 · New England Journal of Medicine
72. Lowering blood pressure to prevent stroke recurrence: a systematic review of long-term randomized trials
    Carlos A. Feldstein · 2014 · Journal of the American Society of Hypertension
73. Effect of Baseline Kidney Function on the Risk of Recurrent Stroke and on Effects of Intensive Blood Pressure Control in Patients With Previous Lacunar Stroke: A Post Hoc Analysis of the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)
    Adhish Agarwal, Alfred K. Cheung, Jianing Ma, Monique Cho, Man Li · 2019 · Journal of the American Heart Association
74. The Role of Angiotensin II Receptors in Stroke Protection
    Steven G. Chrysant · 2012 · Current Hypertension Reports
75. Effects of renin–angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis
    Yoko M. Nakao, Satoshi Teramukai, Sachiko Tanaka, Shinji Yasuno, Akira Fujimoto, Masato Kasahara, Kenji Ueshima, Kazuhiro Nakao, Shiro Hinotsu, Kazuwa Nakao et al. · 2011 · Diabetes Research and Clinical Practice
76. Trends in Long-Term Mortality and Morbidity in Patients with No Early Complications after Stroke and Transient Ischemic Attack
    Jodi D. Edwards, Moira K. Kapral, Jiming Fang, Richard H. Swartz · 2017 · Journal of Stroke and Cerebrovascular Diseases
77. Control of blood pressure and cardiovascular outcomes in type 2 diabetes
    Hernando Vargas‐Uricoechea, Manuel Felipe Cáceres-Acosta · 2018 · Open Medicine
78. Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge
    In Suck Choi, Ie Byung Park, Ki‐Young Lee, Tae Hoon Ahn, Ju Han Kim, Youngkeun Ahn, Sung-Chull Chae, Hyo-Soo Kim, Young‐Jo Kim, Myeong‐Chan Cho et al. · 2018 · Journal of Cardiovascular Pharmacology and Therapeutics
79. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension
    Flávio Danni Fuchs, Luíz Cesar Nazário Scala, José Fernando Vilela-Martin, Renato Gorga Bandeira de Mello, Francisca Mosele, Paul Kieran Whelton, Carlos Eduardo Poli‐de‐Figueiredo, Paulo Ricardo de Alencastro, Ricardo Pereira e Silva, Miguel Gus et al. · 2016 · Journal of Hypertension
80. Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets?
    Patricio A López-Jaramillo, António Coca, Ramiro Ariel Sanchez, Alberto Zanchetti · 2016 · Hypertension
81. Blood Pressure Goals in Acute Stroke
    Qian‐Hui Guo, Chu‐Hao Liu, Ji‐Guang Wang · 2022 · American Journal of Hypertension
82. Results of the ONTARGET and TRANSCEND studies: an update and discussion
    David Fitchett · 2008 · Vascular Health and Risk Management
83. Risk of Recurrent Stroke in Patients With Silent Brain Infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Imaging Substudy
    Ralph Weber, Christian Weimar, Isabel Wanke, Claudia Möller-Hartmann, Elke Ruth Gizewski, Jon Blatchford, Karin Hermansson, Andrew M. Demchuk, Michael Forsting, Ralph L. Sacco et al. · 2012 · Stroke
84. Telmisartan for the reduction of cardiovascular morbidity and mortality
    Paolo Verdecchia, Fabio Angeli, Giorgio Gentile, Giovanni Mazzotta, Gianpaolo Reboldi · 2011 · Expert Review of Clinical Pharmacology
85. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials
    Vu Hoang, Mahboob Alam, Daniel Addison, Francisco Macedo, Salim S. Virani, Yochai Birnbaum · 2016 · Cardiovascular Drugs and Therapy
86. Hypertension in Chronic Kidney Disease – Role of Arterial Calcification and Impact on Treatment
    Olivier Phan, Michel Burnier, Grégoire Wuerzner, Service of Nephrology · 2014 · European Cardiology Review
87. Cutaneous Manifestations in Internal Malignancy
    Navtej Singh · 2017 · International Journal of Advanced and Integrated Medical Sciences
88. ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation
    Mohamed Ahmed Sobhy, Adel Eletriby, Hany Ibrahim Ragy, Hossam Kandil, Mohamed Ayman Saleh, Nabil Mahmoud Farag, Ramez R. Guindy, Ahmed Bendary, Ahmed El Mahmoudy Nayel, Ahmed Shawky et al. · 2024 · Cardiology and Therapy
89. Differences in Ischemic and Hemorrhagic Recurrence Rates among Race-Ethnic Groups in the PRoFESS Secondary Stroke Prevention Trial
    Conrado J. Estol, Philip M. Bath, Philip B. Gorelick, Daniel Cotton, Renée Hebert Martin · 2014 · International Journal of Stroke
90. Update on the Management of Hypertension for Secondary Stroke Prevention
    Luis Castilla‐Guerra, María del Carmen Fernández‐Moreno · 2012 · European Neurology
91. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study
    Chi‐Hung Liu, Pi‐Shan Sung, Yanrong Li, Wen‐Kuan Huang, Tay-Wey Lee, Chin‐Chang Huang, Tsong‐Hai Lee, Tien‐Hsing Chen, Yi‐Chia Wei · 2021 · PLoS Medicine
92. Benefits of Prestroke Use of Angiotensin Type 1 Receptor Blockers on Ischemic Stroke Severity
    Nobukazu Miyamoto, Yasutaka Tanaka, Yuji Ueno, Ryota Tanaka, Nobutaka Hattori, Takao Urabe · 2010 · Journal of Stroke and Cerebrovascular Diseases
93. Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring
    Luis Castilla‐Guerra, María del Carmen Fernández‐Moreno · 2015 · Journal of Stroke
94. Blood pressure lowering and stroke events in type 2 diabetes: A network meta-analysis of randomized controlled trials
    Xie, Xiao-Xu, Liu, Peng, Wan, Fei-Yan, Lin, Shu-Guang, Zhong, Wen-Ling, Yuan, Zhao-Kang, Zou, Jiao-Jiao, Liu, Li-Bin · 2016 · International Journal of Cardiology
95. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
    Helmy M. Siragy · 2011 · Vascular Health and Risk Management
96. Comparing six antihypertensive medication classes for preventing new‐onset diabetes mellitus among hypertensive patients: a network meta‐analysis
    Yang Yang, Huilan Xu · 2017 · Journal of Cellular and Molecular Medicine
97. A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
    Wang · 2009 · Vascular Health and Risk Management
98. Higher plasma renin activity is a risk factor for total mortality in older Japanese individuals: the Takahata study
    Makoto Daimon, Tsuneo Konta, Toshihide Oizumi, Shigeru Karasawa, Wataru Kaino, Kaoru Takase, Yumi Jimbu, Kiriko Wada, Wataru Kameda, Shinji Susa et al. · 2011 · Metabolism
99. The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies
    Stefan Wanderer, Basil Erwin Grüter, Fabio Strange, Sivani Sivanrupan, Stefano Di Santo, Hans Rudolf Widmer, Javier Fandino, Serge Marbacher, Lukas Andereggen · 2020 · Brain Sciences
100. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke
     Veeran Subramaniam, Gregory Y.H. Lip · 2009 · Expert Review of Cardiovascular Therapy